-+ 0.00%
-+ 0.00%
-+ 0.00%

The US Food and Drug Administration is speeding up approval of HYRNUO® by Bayer as a first-line targeted therapy for patients with HER2-mutated non-small cell lung cancer.

Zhitongcaijing·09/10/2026 02:25:08
Listen to the news
The US Food and Drug Administration is speeding up approval of HYRNUO® by Bayer as a first-line targeted therapy for patients with HER2-mutated non-small cell lung cancer.